Based on the new pivotal clinical trial results of NOV03 and CyclASol which were presented at the ASCRS, rethinking DED treatment becomes a reality.
Novaliq uses cookies which are necessary for the proper functioning of its website. We may also use cookies to remember session management, to collect statistics, and to optimize site functionality. Click Agree and proceed to accept cookies and go directly to the site.
Decide which cookies you want to allow.
You can change these settings at any time. However, this can result in some functions no longer being available. For information on deleting the cookies, please consult your browser’s help function.
Learn more about the cookies we use.